Diffuse gliomas corresponding histologically to WHO grade 2 or 3 that are immunohistochemically negative for IDH1 R132H should be sequenced for less common IDH1 and for IDH2 mutations. The gene discussed is IDH2; the disease is central nervous system cancer.